The University of Southampton
×
Filter your search:
University of Southampton Institutional Repository

Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]: a single technology appraisal

Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]: a single technology appraisal
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]: a single technology appraisal
This report is a critique of the company’s submission (CS) to NICE from Astellas Pharma Ltd on the clinical effectiveness and cost effectiveness of enfortumab vedotin with pembrolizumab for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. It identifies the strengths and weaknesses of the CS.
Southampton Health Technology Assessments Centre
Maund, Emma
c9733167-eafe-44e5-b418-5ace79161402
Chinnery, Fay
57bc237a-8d07-4af1-b469-e801dff5715b
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Maund, Emma
c9733167-eafe-44e5-b418-5ace79161402
Chinnery, Fay
57bc237a-8d07-4af1-b469-e801dff5715b
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67

Maund, Emma, Chinnery, Fay, Cooper, Keith and Shepherd, Jonathan (2024) Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]: a single technology appraisal Southampton Health Technology Assessments Centre 118pp.

Record type: Monograph (Project Report)

Abstract

This report is a critique of the company’s submission (CS) to NICE from Astellas Pharma Ltd on the clinical effectiveness and cost effectiveness of enfortumab vedotin with pembrolizumab for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. It identifies the strengths and weaknesses of the CS.

Text
Enfortumab vedotin EAG report - Other
Available under License Creative Commons Attribution.
Download (1MB)

More information

Published date: 2024
Related URLs:

Identifiers

Local EPrints ID: 506636
URI: http://eprints.soton.ac.uk/id/eprint/506636
PURE UUID: a1c51a96-b13b-47bd-8e2d-de279fe1eb05
ORCID for Emma Maund: ORCID iD orcid.org/0000-0002-3998-6669
ORCID for Fay Chinnery: ORCID iD orcid.org/0000-0002-8082-9016
ORCID for Keith Cooper: ORCID iD orcid.org/0000-0002-0318-7670
ORCID for Jonathan Shepherd: ORCID iD orcid.org/0000-0003-1682-4330

Catalogue record

Date deposited: 12 Nov 2025 17:46
Last modified: 13 Nov 2025 02:50

Export record

Contributors

Author: Emma Maund ORCID iD
Author: Fay Chinnery ORCID iD
Author: Keith Cooper ORCID iD
Author: Jonathan Shepherd ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information
Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×